{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-070820","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.504779+00:00","generated_at":"2026-06-21T22:39:07.918462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CorMedix reports Q3 net loss of $6.9M; provides DefenCath regulatory and NTAP updates","bullets":["Net loss of $6.9M ($0.17 per share) improved from $8.6M loss ($0.22) in Q3 2021.","Cash and short-term investments $59.0M; sufficient to fund operations through 2023.","CMS increased NTAP reimbursement for DefenCath from $4,387.50 to $14,259.38 per visit.","CMO implemented >95% of FDA corrective actions; NDA resubmission target end of Q1 2023.","R&D expense decreased 51% to $2.3M; SG&A increased 21% to $4.6M on pre-launch activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-070820","json":"https://secwatch.observer/filing/0001213900-22-070820.json","markdown":"https://secwatch.observer/filing/0001213900-22-070820.md","text":"https://secwatch.observer/filing/0001213900-22-070820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/0001213900-22-070820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/ea168353-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:39:07.918462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e97bb914ca87c93f1d9305c5fdffc8346f4646b","claim":"CorMedix Inc. reported the third quarter of 2022 results: net income $6.9 million, EPS $0.17 per share.","evidence_excerpt":"For the third quarter of 2022, CorMedix recorded a net loss of $6.9 million, or $0.17 per share, compared with a net loss of $8.6 million, or $0.22 per share, in the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/0001213900-22-070820-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Net income","value":"$6.9 million"},{"label":"EPS","value":"$0.17 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"554a880b964147939ded318451c56502c87c058d","claim":"CorMedix Inc. reported the nine months ended September 30, 2022 results: net income $21.5 million, EPS $0.54 per share.","evidence_excerpt":"For the nine months ended September 30, 2022, CorMedix recorded a net loss of $21.5 million, or $0.54 per share, compared with a net loss of $20.4 million, or $0.54 per share, in the first nine months of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/0001213900-22-070820-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Net income","value":"$21.5 million"},{"label":"EPS","value":"$0.54 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}